The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood.

What Was Tested

Researchers studied Nicotine in this randomized controlled trial publication.

This study evaluated the relationship between smoking cessation treatment outcome and the DRD2 polymorphism.

Participants were 134 smokers who took part in a larger clinical trial evaluating the effects of an antidepressant medication (venlafaxine or placebo) plus standard care (brief counseling and nicotine replacement therapy).

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Nicotine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Nicotine study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Nicotine group a baseline to be compared against.

What Was Measured

This study evaluated the relationship between smoking cessation treatment outcome and the DRD2 polymorphism.

Participants were 134 smokers who took part in a larger clinical trial evaluating the effects of an antidepressant medication (venlafaxine or placebo) plus standard care (brief counseling and nicotine replacement therapy).

PubMed files the paper under topics including Affect, Antidepressive Agents, Second-Generation, Counseling, Cyclohexanols, Ganglionic Stimulants, Genotype and Nicotine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Nicotine.

The publication is from 2004 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the related Therapeutic nicotine (patch, non-peptide) library page, all human trials.